120 related articles for article (PubMed ID: 37524453)
1. Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation.
Chen M; Zuo S; Chen S; Li X; Zhang T; Yang D; Zou X; Yang Y; Long H; Peng R; Yuan H; Guo B; Liu L
J Pharmacol Sci; 2023 Sep; 153(1):38-45. PubMed ID: 37524453
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice.
Cui B; Hou X; Liu M; Li Q; Yu C; Zhang S; Wang Y; Wang J; Zhuang S; Liu F
Front Pharmacol; 2022; 13():829630. PubMed ID: 36046818
[TBL] [Abstract][Full Text] [Related]
3. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Liu L; Liu F; Guan Y; Zou J; Zhang C; Xiong C; Zhao TC; Bayliss G; Li X; Zhuang S
FASEB J; 2021 Jul; 35(7):e21715. PubMed ID: 34143514
[TBL] [Abstract][Full Text] [Related]
4. Cross talk between lysine methyltransferase Smyd2 and TGF-β-Smad3 signaling promotes renal fibrosis in autosomal dominant polycystic kidney disease.
Li LX; Zhang L; Agborbesong E; Zhang X; Zhou JX; Li X
Am J Physiol Renal Physiol; 2022 Aug; 323(2):F227-F242. PubMed ID: 35759739
[TBL] [Abstract][Full Text] [Related]
5. STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.
Pan K; Hu B; Wang L; Yuan J; Xu W
J Mol Neurosci; 2022 Sep; 72(9):2030-2044. PubMed ID: 35939202
[TBL] [Abstract][Full Text] [Related]
6. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
[TBL] [Abstract][Full Text] [Related]
7. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
8. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
10. The modulatory effect of sodium molybdate against cisplatin-induced CKD: Role of TGF-β/Smad signaling pathway.
El-Waseif EG; Sharawy MH; Suddek GM
Life Sci; 2022 Oct; 306():120845. PubMed ID: 35917941
[TBL] [Abstract][Full Text] [Related]
11. Ginkgo biloba leaf extract mitigates cisplatin-induced chronic renal interstitial fibrosis by inhibiting the epithelial-mesenchymal transition of renal tubular epithelial cells mediated by the Smad3/TGF-β1 and Smad3/p38 MAPK pathways.
Wei C; Zhang Y; Zhong X; Lu S; Zou X; Yang Y; Huang S; Huang Z
Chin Med; 2022 Feb; 17(1):25. PubMed ID: 35189929
[TBL] [Abstract][Full Text] [Related]
12. Rehmannia glutinosa Libosch and Cornus officinalis Sieb herb couple ameliorates renal interstitial fibrosis in CKD rats by inhibiting the TGF-β1/MAPK signaling pathway.
Zhu JH; Wang L; Ma ZX; Duan JA; Tao JH
J Ethnopharmacol; 2024 Jan; 318(Pt B):117039. PubMed ID: 37579922
[TBL] [Abstract][Full Text] [Related]
13. NDRG2 knockdown promotes fibrosis in renal tubular epithelial cells through TGF-β1/Smad3 pathway.
Jin Z; Gu C; Tian F; Jia Z; Yang J
Cell Tissue Res; 2017 Sep; 369(3):603-610. PubMed ID: 28646304
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
15. Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
Su H; Meng C; Xu J; Su Z; Xiao C; Yang D
Cell Death Dis; 2022 Oct; 13(10):890. PubMed ID: 36270984
[TBL] [Abstract][Full Text] [Related]
16. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation.
Chen H; Yang T; Wang MC; Chen DQ; Yang Y; Zhao YY
Phytomedicine; 2018 Mar; 42():207-218. PubMed ID: 29655688
[TBL] [Abstract][Full Text] [Related]
17. The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis.
Lok SWY; Yiu WH; Li H; Xue R; Zou Y; Li B; Chan KW; Chan LYY; Leung JCK; Lai KN; Tang SCW
Clin Sci (Lond); 2020 Nov; 134(21):2873-2891. PubMed ID: 33078834
[TBL] [Abstract][Full Text] [Related]
18. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
19. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
20. Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis.
Park JY; Yoo KD; Bae E; Kim KH; Lee JW; Shin SJ; Lee JS; Kim YS; Yang SH
Am J Physiol Renal Physiol; 2022 May; 322(5):F553-F572. PubMed ID: 35311382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
